Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 to 65 years
• Men only
• No healthy volunteers
• Adult, Older adult

About this study

Official title: A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety And Toleration Of Differing Doses and Combinations Of Immediate and Modified Release Formulations Of UK-369,003 and Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction

Conditions

Impotence

Being tested

UK0369,003, Cialis (Tadalafil)

Medical subject headings

Erectile Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• UK0369,003Drug

• Cialis (Tadalafil)Drug

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Assessment of duration of action, safety & toleration of the investigational drug and Cialis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted15 Sep 2005 (estimated)
2. Study startFeb 2005
3. Study completionJun 2005

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for ImpotenceStudies of the same condition, open and under way.
• More trials run by PfizerThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.